Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Rheumatology Women's Health Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Clinical Trial Active — Not Recruiting NCT03312465

Anatomical Shoulder Domelock System Study

Anatomical Shoulder Domelock System Study — Active Not Recruiting • Rheumatology • NCT03312465.

📅 25 Aug 2026 ⏱ 1 min read
Active — Not Recruiting
Check the registry for current status and eligibility criteria.
Status
Active — Not Recruiting
NCT ID
NCT03312465
Start
2017-09-28
Completion
2032-12-09
ClinicaliQ Trial Snapshot
  • Anatomical Shoulder Domelock System Study — Active Not Recruiting • Rheumatology • NCT03312465.
  • This study confirms a new shoulder replacement system is safe and works well by checking patient scores, X-rays and complications.

Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.

Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

The objectives of this study are to confirm safety and performance of the Anatomical Shoulder Domelock System when used in hemi or total shoulder arthroplasty by analysis of standard scoring systems, radiographs and adverse event records. Conditions: Avascular Necrosis, Revision Surgery, Conditions Consequent to Earlier Operations, Arthritis, Rheumatoid, Arthritis, Degenerative, Arthritis;Traumatic Interventions: AS Domelock System Lead Sponsor: Zimmer Biomet Planned Enrollment: 73 participants

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Webinar
JAK Inhibitors: Updated Safety Signals, Patient Selection and Post-ORAL Surveillance
Rheumatology · 0.5 · 05 Apr 2026
Recorded webinar focused on JAK inhibitors in rheumatology and immune-mediated inflammatory disease. Reviews JAK-STAT signalling, patient selection, ORAL Surveillance safety signals, cardiovascular…
Watch webinar →
Podcast
JAK Inhibitors: Updated Safety Signals, Patient Selection and Post-ORAL Surveillance
Rheumatology · 00:16:21 · 03 Apr 2026
JAK inhibitors target the JAK-STAT pathway, interrupting intracellular cytokine signalling across several inflammatory diseases. ORAL Surveillance reshaped risk assessment after higher rates…
Listen →
Guideline
Systemic Lupus Erythematosus (BSR Guidelines)
Rheumatology · 27 Mar 2026
Diagnose SLE using combination of clinical features plus positive ANA with anti-dsDNA or anti-Smith antibodies, and refer to rheumatology if SLE suspected…
View guideline →
Guideline
2023 EULAR Recommendations for Systemic Lupus Erythematosus
Rheumatology · 30 Mar 2026
This EULAR guideline addresses 2023 EULAR Recommendations for Systemic Lupus Erythematosus in Rheumatology. Use it to review current recommendation wording, eligibility criteria,…
View guideline →
Guideline
Osteoarthritis: Care and Management (NICE CG177)
Rheumatology · 27 Mar 2026
Offer all patients with osteoarthritis structured information about self-management, weight management, and both land-based and aquatic exercise programmes as first-line treatment before…
View guideline →
Guideline
Axial Spondyloarthritis: Diagnosis and Management (NICE NG65)
Rheumatology · 27 Mar 2026
Refer adults to rheumatology if they present with chronic back pain (≥3 months) plus any of: inflammatory back pain features, elevated inflammatory…
View guideline →